Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase EARLY_PHASE1 2

Status

Not yet recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Other 1

Conditions

Endometrial Neoplasms 3Obesity 2Endometrial Hyperplasia 2Weight Loss 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Opioid-Related Disorders 1Lymphoma, Follicular 1Hyperplasia 1Breast Neoplasms 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × Tirzepatide × Clear all
NCT07078838 2026-06-04

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Not yet recruiting
40 enrolled
GynecologicOther

Endometrial Hyperplasia, Hyperplasia, Obesity, Endometrial Neoplasms

NCT07605247 2026-05-22

TREAT-EC

Rutgers, The State University of New Jersey

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Endometrial Neoplasms

NCT06073184 2025-06-10

WE-FiERCE

University Health Network, Toronto

Phase 2 Not yet recruiting
71 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡